The estimated Net Worth of John Lambert is at least $3.77 Milione dollars as of 2 November 2016. John Lambert owns over 2,775 units of Immunogen stock worth over $3,765,076 and over the last 21 years John sold IMGN stock worth over $0.
John has made over 42 trades of the Immunogen stock since 2004, according to the Form 4 filled with the SEC. Most recently John bought 2,775 units of IMGN stock worth $4,690 on 2 November 2016.
The largest trade John's ever made was exercising 80,000 units of Immunogen stock on 14 February 2012 worth over $316,000. On average, John trades about 10,342 units every 79 days since 2003. As of 2 November 2016 John still owns at least 120,521 units of Immunogen stock.
You can see the complete history of John Lambert stock trades at the bottom of the page.
John's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... e Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: